This preparation combines CJC-1295 (a GHRH analogue) with Ipamorelin (a selective ghrelin receptor agonist) in one vial. Engaging two distinct pathways — GHRH and ghrelin — is among the most frequently used designs in research on synergistic growth hormone secretion. This 10mg vial suits research with medium to larger volume requirements.
Third-party testing covers purity of ≥99.4%, compound identification by LC-MS, and endotoxin levels below 0.5 EU/mg.
In lyophilised powder form, store at 2–8 °C protected from light. After reconstitution with BAC water, maintain at 2–8 °C. Available for delivery throughout Indonesia, packaged to preserve product condition.
For in-vitro and laboratory research use only.